98 related articles for article (PubMed ID: 25193431)
1. The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
Sharma S; Britten CD; Mortimer J; Kulkarni S; Quinlan M; Liu A; Scott JW; George D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):867-74. PubMed ID: 25193431
[TBL] [Abstract][Full Text] [Related]
2. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
Infante JR; Ramanathan RK; George D; Tan E; Quinlan M; Liu A; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2015 Apr; 75(4):729-37. PubMed ID: 25648347
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
5. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.
de Weger VA; Goel S; von Moos R; Schellens JHM; Mach N; Tan E; Anand S; Scott JW; Lassen U
Cancer Chemother Pharmacol; 2018 Jan; 81(1):73-80. PubMed ID: 29101463
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors.
Mostafa NM; Chiu YL; Rosen LS; Bessudo A; Kovacs X; Giranda VL
Cancer Chemother Pharmacol; 2014 Sep; 74(3):583-91. PubMed ID: 25053388
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
Milowsky MI; Dittrich C; Durán I; Jagdev S; Millard FE; Sweeney CJ; Bajorin D; Cerbone L; Quinn DI; Stadler WM; Rosenberg JE; Lochheed M; Sen P; Squires M; Shi M; Sternberg CN
Eur J Cancer; 2014 Dec; 50(18):3145-52. PubMed ID: 25457633
[TBL] [Abstract][Full Text] [Related]
9. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
Henney HR; Shah J
Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
11. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
[TBL] [Abstract][Full Text] [Related]
12. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
13. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
14. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
Guivarc'h PH; Vachon MG; Fordyce D
Clin Ther; 2004 Sep; 26(9):1456-69. PubMed ID: 15531008
[TBL] [Abstract][Full Text] [Related]
15. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.
Banerji U; Camidge DR; Verheul HM; Agarwal R; Sarker D; Kaye SB; Desar IM; Timmer-Bonte JN; Eckhardt SG; Lewis KD; Brown KH; Cantarini MV; Morris C; George SM; Smith PD; van Herpen CM
Clin Cancer Res; 2010 Mar; 16(5):1613-23. PubMed ID: 20179232
[TBL] [Abstract][Full Text] [Related]
16. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
17. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
[TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
[TBL] [Abstract][Full Text] [Related]
20. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
